T-cell masthead image

Paper

Paper

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

  • External Link
COVID-19: Lai, C.Y., To, A., Wong, T.A.S., Lieberman, M.M., Clements, D.E., Senda, J.T., Ball, A.H., Pessaint, L., Andersen, H., Donini, O., Lehrer, A.T. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. 2021.
Publication

Frontiers in Immunity CoVaccine HT™ Publication

  • External Link
COVID-19: Haun, B.K., Lai, C.Y., Williams, C.A., Wong, T.A.S., Lieberman, M.M., Pessaint, L., Andersen, H., Lehrer, A.T. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. 2020.
Paper

Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide

  • External Link
Ebola: Chisholm F, Kang JT, Dong M, Lewis K, Namekar M, Lehrer AT, Randolph TW. Thermostable Ebola Virus Vaccine Formulations Lyophilized in the Presence of Aluminum Hydroxide. Eur. J. Pharm. Bipharm. 2019. 136: 213-20.
Paper

Thermal stability and epitope integrity of a lyophilized ricin toxin subunit vaccine

  • External Link
Westfall J, Yates JL, Van Slyke G, Ehrbar D, Measey T, Straube R, Donini O, Mantis NJ, Thermal stability and epitope integrity of a lyophilized ricin toxin subunit vaccine. Vaccine. 36(40):5967-5976
Paper

Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication

  • External Link
Yates JL, Leadbetter E, Mantis NJ. Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication. Hum Vaccin Immunother. 14(8):2053-2057
Paper

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

  • PDF (240.80 KB)
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Paper

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

  • PDF (240.80 KB)
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Paper

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

  • External Link
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Paper

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

  • External Link
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Paper

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy

  • External Link
North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici L, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotech 2016; 226: 24-34.